Home Noticias de Salud Family Centers Health Centers Resources My Health Manager
  Search
  PersonalMD Services  
  Family Health
  Women's Health
  Children's Health
  Men's Health
  Senior's Health
   
  Health Centers
  Alternative Medicine
  Cardiac Care Center
  Cancer Center
  Emergency Dept
  Medical Advances
  Nutrition Central
  Pulmonary Center
  Sports Medicine
  Travel Medicine
   
  Resources
  Drug Interaction
  Drugs & Medications
  Health Encyclopedia


     
   
Spud-based vaccine may prevent the runs

LOS ANGELES, May 29 (Reuters Health) - Potatoes engineered with Norwalk virus, which along with related viruses causes most cases of diarrhea in the US, can induce an immune response in humans, according to the results of a study.

The work builds on earlier work by Dr. Charles Arntzen of the Boyce Thompson Institute for Plant Research in Ithaca, New York, and colleagues. His group had shown in 1998 that bioengineered potatoes could induce antibodies against a toxin produced by E. coli bacteria, another common cause of diarrhea.

In an interview with Reuters Health at the recent annual meeting of the American Society for Microbiology, Arntzen said that Norwalk virus will probably require an oral vaccine to induce protective immunity in the gut. As he reported at the meeting, 19 of 20 volunteers who ate the genetically engineered potatoes developed serum and mucosal antibodies against Norwalk virus.

However, he said it is unclear whether this is enough of an immune response to fight off an infection. "We have no way of determining how strong--what is a correlate of protection--because the correlate of protection has never been established for Norwalk virus," he said. "We don't know if we elicited enough antibody or not. We'll only get that as we begin testing people."

His group is planning another trial in the US, which he said could lead to a trial where the volunteers would be challenged with the virus. Arntzen said they are also interested in testing this vaccine in developing countries, particularly Mexico, since the virus strains and the intestinal microflora will be different from the US.

Although the vaccine is still in the early stages of development, he is optimistic about its prospects. "We do anticipate that Norwalk virus is very probably going to be our first vaccine that hits the licensure stage and could go into commercial development," he said.


DISCUSSION
See what PersonalMD members have to say about this article.
 

 

 

 

Register About Us Emergency Contact us Privacy Policy Help Center
Resources Health Centers Family Health